ScholarIQanswers from OpenAlex
University of Alabama at Birmingham
InstitutionResearch output, impact & collaborations
University of Alabama at Birmingham is a institution indexed in ScholarIQ from OpenAlex.
What is known about University of Alabama at Birmingham?
ScholarIQrecord summary
University of Alabama at Birmingham is a research organisation in Birmingham, US. OpenAlex records 157,774 works and 16,293,611 citations for it. 29,386 researchers list it as their most recent affiliation.
How many works does University of Alabama at Birmingham have?
ScholarIQindexed works
University of Alabama at Birmingham has 157,774 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does University of Alabama at Birmingham have?
ScholarIQcitation count
University of Alabama at Birmingham has 16,293,611 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at University of Alabama at Birmingham?
ScholarIQresearcher count
University of Alabama at Birmingham has 29,386 researchers in the ScholarIQ index.
What is the average h-index at University of Alabama at Birmingham?
ScholarIQavg h-index
University of Alabama at Birmingham has an average h-index of 67.8 in OpenAlex.
What is the ROR of University of Alabama at Birmingham?
ScholarIQror
The ROR for University of Alabama at Birmingham is on the source record.
What is the OpenAlex record for University of Alabama at Birmingham?
ScholarIQopenalex
The OpenAlex for University of Alabama at Birmingham is on the source record.
Who are the most-cited researchers behind University of Alabama at Birmingham?
ScholarIQtop researchers by citations
What are the most-cited papers on University of Alabama at Birmingham?
ScholarIQmost cited works
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Ravindra L. Mehta, John A. Kellum, Sudhir V. Shah, Bruce A. Molitoris, Claudio Ronco, David G. Warnock, Adeera Levin, the Acute Kidney Injury Network
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman, Michael S. Lawrence, Douglas Voet, Rui Jing, Kristian Cibulskis, Andrey Sivachenko, P. Stojanov, Aaron McKenna, Eric S. Lander, Getz Gs, Marcin Imielinski, Elena Helman, BRYAN HERNANDEZ, Nam Pho, M. Meyerson, Gordon Saksena, Andrew D. Cherniack, Stephen E. Schumacher, Barbara Tabak, Scott L. Carter, Huy Nguyen, A H Crenshaw, Rameen Beroukhim, Wendy Winckler, Hailei Zhang, S Shukla, Lynda Chin, Michael Noble, Doug Voet, Nils Gehlenborg, Daniel DiCara, Spring Yingchun Liu, Lihua Zou, Pei Lin, Juok Cho, Marc-Danie Nazaire, Jim Robinson, Helga Thorvaldsdóttir, Jill Mesirov, Chang‐Jiun Wu, Bruce E. Johnson, David Kwiatkowski, Bruce E. Johnson, Carrie Sougnez, Stacey Gabriel, Robert C. Onofrio, Kristin Ardlie, Andy Chu, Hye-Jung E. Chun, Andrew J. Mungall, Erin Pleasance, A. Gordon Robertson, Payal Sipahimalani, Dominik Stoll, Miruna Balasundaram, İnanç Birol, Yaron S.N. Butterfield, Eric Chuah, Robin Coope, Richard Corbett, Noreen Dhalla, Ranabir Guin, An He, Carrie Hirst, Martin Hirst, Robert A. Holt, Darlene Lee, Haiyan I. Li, Michael Mayo, Richard A. Moore, Karen Mungall, Ka Ming Nip, Jacqueline E. Schein, Jared R. Slobodan, Angela Tam, Nina Thiessen, Richard Varhol, Thomas Zeng, Yongjun Zhao, Steven J.M. Jones, Marco A. Marra, Elizabeth Chun, Andy Mungall, Gordon Robertson, Adam Olshen, Alexei Protopopov, J Zhang, Xiaojia Ren, Jinhua Zhang, J Zhang, Angela Hadjipanayis, Peng‐Chieh Chen, Raju Kucherlapati, Psalm Haseley, Eunjung Lee, P H Park, So Lee, Ruibin Xi, Lixing Yang, Nicholas D. Socci
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Jay M. Edelberg, Shaun G. Goodman, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Guillaume Lecorps, Kenneth W. Mahaffey, Angèle Moryusef, Robert Pordy, Kirby Quintero, Matthew T. Roe, William J. Sasiela, Jean‐François Tamby, Pierluigi Tricoci, Harvey D. White, Andreas M. Zeiher
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst, Lewis J. Rubin, Walker Long, Michael D. McGoon, Stuart Rich, David B. Badesch, Bertron Μ. Groves, Victor F. Tapson, Robert C. Bourge, Bruce H. Brundage, Spencer K. Koerner, David Langleben, Cesar A. Keller, Srinivas Murali, Barry F. Uretsky, Linda Clayton, Maria M. Jöbsis, Shelmer D. Blackburn, Denise Shortino, James W. Crow
UALCAN: An update to the integrated cancer data analysis platform
Darshan S. Chandrashekar, Santhosh Kumar Karthikeyan, Praveen Kumar Korla, Henalben Patel, Ahmedur Rahman Shovon, Mohammad Athar, George J. Netto, Zhaohui Qin, Sidharth Kumar, Upender Manne, Chad J. Creighton, Sooryanarayana Varambally
How much of the research on University of Alabama at Birmingham is open access?
ScholarIQopen access share
75%OPEN ACCESS